MSHLEnfortumab vedotin Powder For Concentrate For Solution For Infusion 20 mg, 30 mg
Treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.